National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011

BACKGROUND: Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF). However, national practice patterns in the use of spironolactone in China are unk...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Wenchi, Murugiah, Karthik, Downing, Nicholas, Li, Jing, Wang, Qing, Ross, Joseph S, Desai, Nihar R, Masoudi, Frederick A, Spertus, John A, Li, Xi, Krumholz, Harlan M, Jiang, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599529/
https://www.ncbi.nlm.nih.gov/pubmed/26071031
http://dx.doi.org/10.1161/JAHA.114.001718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599529/
https://www.ncbi.nlm.nih.gov/pubmed/26071031
http://dx.doi.org/10.1161/JAHA.114.001718

Ejemplares similares